2 May 2018

Dear Dr O’Bryan,

Trial Number: 250  
Title: Comparing the sterility and visibility of surgical marking pens available in Australia

Please find enclosed the final approval for the above trial.

Approval is for 5 years and will expire on 2 May 2023 for the above trial.

It is your responsibility to contact the Coordinator immediately should any of the following occur:

- Serious or unexpected adverse effects on the participants
- Any proposed changes to the protocol, including extension of time or any changes in treatment other than as was stipulated in the proposals.
- Any events which might affect the continuing ethical acceptability the project.
- The project is discontinued before the expected date of completion.

In addition, you will be required to report on the progress of your project annually and at the conclusion of the project. Failure to report as required will result in suspension of approval to proceed further with the project. A copy of the reporting tool will be forwarded at the appropriate time.

The Ethics Committee wishes you all the best with this research and looks forward to seeing your results.

The Committee wishes you well with the research and looks forward to your first report. A reminder will be sent prior to the due date.

Should you require any further information or clarification please contact me at any time – BaldwinMonique@ramsayhealth.com.au.

Yours sincerely

[Signature]

Dr Monique Baldwin  
HREC Coordinator

This HREC is constituted and operates in accordance with the National Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research (2007). The processes used by this HREC to review multi-centre research proposals have been certified by the National Health and Medical Research Council.